NEW YORK (GenomeWeb) – Seattle-based cancer immunotherapy company Juno Therapeutics has acquired AbVitro of Boston for approximately $78 million in cash and almost 1.3 million shares of its stock, the company said today.

In addition, Juno and Celgene have agreed in principle on a deal under which Celgene will license a subset of AbVitro's technology and have options to certain potential products deriving from it.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.